StockNews.AI
ARVN
StockNews.AI
110 days

BREAKING: Block & Leviton Investigating Arvinas, Inc. (ARVN) For Securities Fraud After Shares Fall Over 20%; Investors Encouraged to Contact the Firm to Potentially Recover Losses

1. Arvinas shares dropped over 20% after vepdegestrant development halted. 2. The company discontinued two Phase 3 studies of the drug. 3. Oppenheimer & Co. expressed surprise over Arvinas' management decisions. 4. Block & Leviton is investigating potential securities law violations. 5. Investors are encouraged to contact Block & Leviton for recovery options.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The abrupt halt in drug development signals severe company risk, impacting investor trust. Historical examples show drastic declines in stock prices following product development failures.

How important is it?

The cessation of drug trials and investigations into potential legal violations significantly harm ARVN’s market position and investor confidence.

Why Short Term?

The immediate impact of the stock drop due to halted trials will affect short-term investor sentiment. Recovery may take time as confidence rebuilds.

Related Companies

PFEMRKAAPL
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Arvinas, Inc. (Nasdaq: ARVN) for potential securities law violations. Investors who have lost money in their Arvinas, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/arvn. What is this all about? Shares of Arvinas fell over 20% in intraday trading today, after the company and its partner Pfizer announced they would discontinue development of vepdegestrant, an oral SERD for HR-positive breast cancer. The move eliminated two planned Phase 3 studies, following the termination of VERITAC-3 in January. According to The Fly, Oppenheimer & Co. “was surprised by the announcement” and questioned whether “Arvinas’ management isn’t telling us the whole story.” Arvinas had repeatedly pointed to clinical progress for vepdegestrant and the drug’s commercial opportunity, leaving investors caught off guard by the abrupt pivot. Who is eligible? Anyone who purchased Arvinas, Inc. common stock and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more. What is Block & Leviton doing? Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money. What should you do next? If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at shareholders@blockleviton.com, or by phone at (888) 256-2510. Whistleblower? If you have non-public information about Arvinas, Inc., you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange Commission under their whistleblower program. Whistleblowers who provide original information to the SEC may receive rewards of up to 30% of any successful recovery. For more information, contact Block & Leviton at shareholders@blockleviton.com or by phone at (888) 256-2510. Why should you contact Block & Leviton? Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website www.blockleviton.com, call (888) 256-2510 or email shareholders@blockleviton.com with any questions. This notice may constitute attorney advertising. CONTACT:BLOCK & LEVITON LLP260 Franklin St., Suite 1860Boston, MA 02110Phone: (888) 256-2510Email: shareholders@blockleviton.com 

Related News